News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Affinium Pharmaceuticals Closes US$18 Million Series A to Advance Clinical Development of Novel Antibacterial Compound



3/26/2007 12:57:57 PM

TORONTO--(BUSINESS WIRE)--Affinium Pharmaceuticals, Inc., a privately held developer of a novel class of oral antibacterial therapeutics, announces the closing of its US$18 million Series A financing. Affinium will use the proceeds from the financing to fund development of its lead candidate through Phase 2 clinical trials. The international financing was led by Forward Ventures and includes new investors Oxford Bioscience Partners, SV Life Sciences, and existing investor Genesys Capital Partners.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES